Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced the launch of new branding for its upcoming oncology clinical trials. The trials combine Genprex’s lead drug candidate, REQORSA(TM) (quaratusugene ozeplasmid), with AstraZeneca’s Tagrisso(R) (osimertinib), which received U.S. Food and Drug Administration (“FDA”) Fast Track Designation … Continue reading “NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Launch of New Branding for Upcoming Combination Clinical Trials”
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has received conditional FDA acceptance of the proprietary name REQORSA(TM), its lead drug candidate for treatment of non-small cell lung cancer. The drug candidate was known previously by the laboratory designation GPX-001. The approval of the new … Continue reading “NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Conditional FDA Acceptance of Proprietary Name for Lead Drug Candidate”
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced the promotion of Eric Chapdelaine to vice president of manufacturing. According to the update, Chapdelaine’s promotion is a result of the company’s achievement of key manufacturing milestones to support upcoming clinical trials of its lead drug … Continue reading “NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints Eric Chapdelaine to Senior Manufacturing Team”
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, is slated to present at an upcoming LD Micro virtual event. GNPX’s Zoom presentation is scheduled for Wednesday, Oct. 14, at 11 a.m. ET. The presentation will feature Genprex president and CEO Rodney Varner, who will deliver … Continue reading “NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO Scheduled to Present at LD Micro Event”
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced that it will present at the Alliance for Regenerative Medicine’s (“ARM”) virtual Cell and Gene Meeting on the Mesa, which is set to take place October 12-16, 2020. Genprex’s executive vice president and COO Michael Redman … Continue reading “NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Cell and Gene Therapy Sector’s Foremost Annual Conference”
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced it has named Thomas C. Gallagher, Esq. as its senior vice president of Intellectual Property and Licensing. According to the update, Gallagher has extensive experience in the area of biotechnology intellectual property (“IP”) law, business … Continue reading “NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Appoints Seasoned Biotech Executive to Advance Expanding IP Estate”
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has appointed William E. Gannon Jr., MD, MBA, as vice president of Regulatory Affairs. With more than three decades of experience in the biotech and pharmaceutical industries and an impressive background in oncology and gene therapy, Gannon … Continue reading “NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints New VP to Oversee Regulatory Affairs”
Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to … Continue reading “Genprex Inc. (NASDAQ: GNPX) Starts Presentation at The LD 500”
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it joins the lineup of presenters at this year’s LD 500 Virtual Investor Conference. The annual LD Conference spotlights some of the most prominent companies in the micro-cap world, and also includes interviews and keynotes … Continue reading “NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Invited to Present at Prestigious LD 500 Virtual Investor Conference”
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, on Thursday announced participation by its chairman and CEO, Rodney Varner, in a second-round live interview on the “Big Biz Show,” an emmy-award winning nationally syndicated TV and radio show. A replay of the interview is available … Continue reading “NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) CEO Again Featured on ‘Big Biz Show,’ to Present at Proactive’s One2One Virtual Investor Forum”
